芦可替尼治疗高危原发性骨髓纤维化2例并文献复习  

Treatment of 2 cases of high risk primary myelofibrosis with ruxolitinib and literature review

作　　者：许霁虹[1] 王洪敏[1] 姜明[1] 张硕[1] 韩雪[1] 张丽萍[1] Xu Jihong;Wang Hongmin;Jiang Ming;Zhang Shuo;Han Xue;Zhang Liping(Department of Hematology,the First Hospital of Qiqihar,Heilongjiang Qiqihar 161005,China)

机构地区：[1]齐齐哈尔市第一医院血液科,黑龙江齐齐哈尔161005

出　　处：《现代肿瘤医学》2018年第22期3650-3652,共3页Journal of Modern Oncology

摘　　要：目的:观察芦可替尼治疗高危原发性骨髓纤维化的临床疗效和不良反应。方法:2017年7月和9月齐齐哈尔市第一医院收治的2例诊断为高危的原发性骨髓纤维化的患者口服芦可替尼前后血常规、脾脏大小、体重的变化情况。结果:2例患者随访5～7个月,脾脏缩小、体重增加、消耗症状消失。结论:芦可替尼能提高高危原发性骨髓纤维化生活质量,使患者临床症状改善,且耐受性良好,具有良好的治疗前景。Objective： To observe the clinical efficacy and adverse reactions of ruxolitinib in the treatment of high risk primary myelofibrosis. Methods： In July 2017 and September,2 patients with primary myelofibrosis who were diagnosed as high risk in Qiqihar First Hospital were examined for blood routine,spleen and body weight changes before and after oral administration. Results： 2 patients were followed up for 5 ～ 7 months. The spleen was reduced,body weight increased and the consumptive symptoms disappeared. Conclusion： Ruxolitinib can improve the quality of life of high risk primary myelofibrosis,improve the patient＇s clinical with well tolerability,and a good treatment prospect.

关 键 词：芦可替尼 高危 原发性骨髓纤维化 

分 类 号：R733[医药卫生—肿瘤]